What Happened?
The pills Americans take every day are increasingly made overseas. Generic drug manufacturers told lawmakers last week that low prices, foreign competition, and federal policies have made it harder to keep production running in the U.S. One economist told Senators that the U.S. now produces 27 percent of the medicine it uses, down from 72 percent in 2002.
Why Does it Matter to Me?
One of the most widespread impacts has been drug shortages.
As of June, the American Society of Health-System Pharmacists reported 227 active drug shortages nationwide.
The market value of the U.S. generic pharmaceutical manufacturing industry fell at a compound annual growth rate of 7.8 percent from 2021 to 2026, according to IBISWorld.
When overseas supply chains face disruptions, Americans who depend on generic drugs feel the effects, the Senate hearing found.
Both Sides, Now
Hearing chairman Sen. Rick Scott (R-FL) and ranking member Sen. Kirsten Gillibrand (D-NY) have worked together on one response: the Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, which would require prescription drug labels to name the original manufacturers of generic drugs and their active ingredients. The bill cleared the Senate Health, Education, Labor and Pensions Committee 21-1 in July and has a companion bill in the House.
One witness, Christine Baeder, president of Apotex USA and LATAM, said her company demolished its North American penicillin plant last year because market conditions made it impossible to sustain.
Witnesses disagreed on whether existing proposals go far enough. Baeder praised a Centers for Medicare and Medicaid Services (CMS) proposal on hospital purchasing incentives, but Kurt Orlofski, CEO of PAI Pharma, pushed back: "It doesn't go far enough. None of the incentive flows back to the manufacturer."
The Trump administration is pursuing a separate track through trade policy. Section 232 tariffs on certain patented pharmaceuticals and their ingredients were set to take effect Sept. 29, though generic drugs are currently exempt from those tariffs.
What Happens Next?
A version of the Securing America's Biosecure Supply Chain and Ensuring Domestic Resilience (BIOSECURE) Act was included in the fiscal year 2026 National Defense Authorization Act, signaling that national security concerns surrounding pharmaceutical and biotechnology supply chains have already influenced major legislation.
The Sept. 29 tariff deadline on patented drugs adds pressure to the broader debate, even as generics remain outside their scope for now. Orlofski, CEO of PAI Pharma, told lawmakers that existing incentive proposals "don't go far enough" because "none of the incentive flows back to the manufacturer."
---
AllCiv makes it easy to stay politically informed and involved.
---
Spot something wrong? Report an issue with this article